Organon & Co. Reports Earnings Below Expectations

Organon & Co. (NYSE:OGN - Get Free Report) announced its quarterly earnings on Thursday, revealing an earnings per share (EPS) of $0.83. This was below the projected consensus estimate of $0.92, falling short by $0.09, according to reports from analysts. The company reported a net margin of 20.30% and achieved an impressive return on equity of 644.70%. Furthermore, Organon & Co. provided an updated forecast for its fiscal year 2025 EPS.

Stock Performance of Organon & Co.

On the day of the announcement, Organon & Co. saw its stock price rise by 8.6%. During trading, the stock increased by $1.27, reaching a price of $15.97. The company's trading volume was notably active, totaling 6,160,096 shares compared to an average volume of 2,694,525 shares. Organon has a quick ratio of 1.21, a current ratio of 1.70, and a debt-to-equity ratio standing at 17.73. Its market capitalization is approximately $4.11 billion, with a price-to-earnings (PE) ratio of 3.17 and a price-to-earnings-growth (PEG) ratio of 0.83. Over the past year, the stock has fluctuated, with a low of $13.87 and a high of $23.10. The 50-day moving average price for the stock is $15.33, while the two-hundred day moving average comes in at $17.54.

Analyst Ratings and Outlook

Analysts on Wall Street have mixed opinions about Organon & Co.'s stock. Notably, TD Cowen upgraded its rating on the shares to a "hold" status in a research report published on January 15th. The coverage on Organon reflects a variety of perspectives, with one analyst issuing a sell rating, two analysts holding, one recommending a buy, and one advocating for a strong buy. According to MarketBeat.com, the overall average analyst rating for Organon & Co. stands at "Hold," with a consensus target price established at $21.33.

About Organon & Co.

Organon & Co. is a global pharmaceutical company founded on March 11, 2020, and is headquartered in Jersey City, New Jersey. The company specializes in science-based healthcare solutions, focusing on prescription therapies in women's health, biosimilars, and established brands. Its mission revolves around developing and delivering innovative health solutions to meet the needs of patients around the world.

Organon, Earnings, Stock